United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STRASBOURG, France--(BUSINESS WIRE)-- #TG4001--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023). Transgene has amended the initial Phase Ib/II trial protocol to enable a more rapid start of this important P

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers

Pfizer Inc (NYSE: PFE) has told the Indian government it wants to produce its COVID-19 vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports, reports Reuters. Last month, the company pulled out its marketing application seeking emergency approval for its COVID-19 shot in India after failing to adhere to the drug regulator's request for a small local study.

Pfizer To Make COVID-19 Jab In India On Faster Clearance Assurance, Export Freedom: Reuters

BioNTech SE

Trailing other leading economies in Covid-19 vaccination, the European Commission said Pfizer and BioNTech have agreed to provide 4 million extra doses.

Europe's Lagging in Vaccination. Pfizer and BioNTech Agree to Provide 4 Million More Doses.

BioNTech SE (NASDAQ: BNTX) says it could have the capacity to make 3 billion doses of the COVID-19 vaccine it developed with Pfizer Inc (NYSE: PFE) in 2022, Bloomberg reports. BioNTech's CEO Ugur Sahin said that the increased manufacturing depends on demand and factors such as the requirement of the additional boost to vaccinations.

Pfizer, BioNTech Predict Increase In Capacity To 3B COVID-19 Vaccine Shots In 2022: Bloomberg

The European Commission said Wednesday that Pfizer and BioNTech will provide 4 million more doses of their coronavirus vaccine in the next two weeks. European Commission President Ursula von der Leyen said the doses are on top of planned dose deliveries.

European Commission says Pfizer and BioNTech to supply 4 million more coronavirus vaccine doses

The two companies' BNT162b2 seems to protect patients against the fast-spreading variant.

Study: Pfizer and BioNTech Vaccine Neutralizes Brazil Coronavirus Variant

LONDON--(BUSINESS WIRE)--ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

The global tally of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 117 million on Tuesday, as a study found the vaccine developed by Pfizer Inc. and German partner BioNTech SE is effective in neutralizing the highly infectious new variant that was first detected in Brazil.

Coronavirus Update: Global tally of COVID cases tops 117 million as study finds Pfizer-BioNTech vaccine works against Brazil variant

Pfizer and BioNTech's Covid-19 vaccine was able to neutralize a coronavirus variant first identified in Brazil in a laboratory test published Monday. In response, BNTX stock popped Tuesday.

Pfizer, BioNTech Covid Vaccine Takes Down Brazil Variant In Lab Test

Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.

Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II

Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.

Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains

Roche Holding AG

The FDA has approved Roche Holdings AG's (OTCMKT: RHHBY) Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with Pfizer Inc's (NYSE: PFE) Lorbrena (lorlatinib). The assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue.

FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer

The COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) works on the Brazil variant, according to a new study. Scientists took blood samples from people who had already received the jab and analysed it against a lab-made reconstruction of the virus.

Coronavirus: Pfizer/BioNTech vaccine works on Brazil variant, study shows

According to a lab study published in the New England Journal of Medicine, Pfizer Inc (NYSE: PFE)/BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine can neutralize a new variant of the coronavirus in Brazil, reported Reuters. The scientists said the neutralizing ability was roughly equivalent to the vaccine's effect on a previous version of the virus from last year.

Pfizer/BioNTech COVID-19 Jab Neutralizes Virus Variant In Brazil: Reuters

Researchers developed an engineered version of the COVID-19 mutation and found that blood samples taken from people who received the vaccine were able to neutralize the variant, according to the study published in the New England Journal of Medicine on Monday.

The New York Post: Pfizer-BioNTech vaccine neutralizes Brazil COVID-19 variant, study shows

The Pfizer/BioNTech coronavirus vaccine was able to combat the Brazil variant of COVID-19, it has been revealed.

Pfizer/BioNTech vaccine shows promise against Brazil coronavirus variant in laboratory testing

Enterprise Products Partners

Alphabet

They look attractive over both the short term and the long term.

3 Stocks That Will Make You Richer in March (and Beyond!)

Saint-Herblain (France) and New York, NY , March 8, 2021 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. (NYSE: PFE) today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress into pivotal Phase 3 studies.

Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

Russian intelligence officials are attempting to cast doubt on the Pfizer coronavirus vaccine, according to a new report from the Wall Street Journal.  Four publications acting as fronts for Russian intelligence are disseminating information that questions the efficacy and safety of the Pfizer vaccine, State Department officials told the Journal.

Russian intelligence has reportedly launched a disinformation campaign attacking the Pfizer COVID-19 vaccine

The opportunity is bigger than it might at first appear.

Are Pregnant Women a Big Market for Pfizer and BioNTech's Vaccine?

Moderna

The competitive landscape is flattening out.

Moderna and Pfizer's Second-Gen Coronavirus Vaccines: What Investors Need to Know

How Worried Should Investors Be About the South African Coronavirus Variant?

AstraZeneca

CureVac B.V

Johnson & Johnson

Novavax

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

2 Green Flags for Pfizer in 2021 and 1 Yellow Flag

Apple

Microsoft

Peloton

Home Depot

The remote economy has served as a tailwind for numerous mega-cap stocks that show a lot of future growth potential. Here are 7 stocks worth buying this year.

News for Pfizer Stock (PFE)